Ŀ÷ ij

10	963
/19/	CE.
1	** 'Y

01-11-02

XPRESS MAIL NO.: EL 806482869 US

DATE OF DEPOSIT: October 19, 2001

PTO/SB/13/PCT (10-00) Approved for use through 10/31/2002 OMB 0651-002 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION		PRIOR APPLICATION EXAMINER	ART UNIT
2543-1-023	CLASS	SUBCLASS		

Address to:

Assistant Commissioner for Patents Washington, D.C. 20231

This is a request for filing a ⊠continuation □ divisional application under 37 CFR 1.53(b) of pending prior international application Number PCT GB00 / 01560 , filed on 4/20/00 entitled COMBINATION OF GLUCOSYLCERAMIDE SYNTHESIS INHIBITORS AND GLYCOLIPID DEGRADING ENZYME IN THERAPY which designated the United States.

Note: 37 CFR 1.53(d) cannot be used to file a continuation or divisional application of an international application which has not

entered the national stage.					
CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
CLAINS	TOTAL CLAIMS (37 CFR 1 16(c))	38 - 20 =	18	x \$ <u>18.</u> =	\$ 324.00
144	INDEPENDENT CLAIMS (37 CFR 1.16(b))	03 - 3 =	0	x \$ <u>0</u> =	0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d)) + \$_0 =				0
	BASIC FEE (37 CFR 1.16(a))				+_740.00
	Total of above Calculations =				
	Reduction by 50% for filing by small entity (Note 37 CFR 1.27).				
	Total =				

	Faclosed	ara tha	specification,	alaime	and	drawing(e)
١.	Enclosed	are me	Specification,	Cialilio	anu	urawing(s).

(status, abandoned, pending, etc.)."

۷. لـــا	Applicant claims small entity status. See 57 GFK 1.27.
3. 🔲	The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No A duplicate copy of this sheet is enclosed.
4. 🗀	A check in the amount of \$ is enclosed.
5. 🗌	Payment by credit card. Form PTO-2038 is attached.
6. 🗌	Application Data Sheet is enclosed. See 37 CFR 1.76.
7. 🗆	Amend the specification by inserting before the first line the sentence: "This application is a continuation of division of international application number PCT / filed

[Page 1 of 2]

Burden Hour Statement This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231

REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION

8. X A declaration under 37 CFR 1.63 is enclosed. Unexecuted 9. X Priority of foreign application number 9909066.4 filed on 4/20/99 in Great Britain
9. Priority of foreign application number 9909066.4, filed on 4/20/99 in Great Britain is claimed under 35 U.S.C. 119(a)-(d).
☐ The certified copy is enclosed.
10. A preliminary amendment is enclosed.
11. Also enclosed: Five (5) Sheets of Informal Drawings (Figure 1 to Figure 11)
Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record).
David A. Jackson, Klauber & Jackson, 411 Hackensack Avenue, Hackensack, New Jersey 07601
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.
\times \downarrow $+$ \sim \sim
October 19, 2001
Date Signature
David A Jackson, Reg. No. 26,742
Typed or printed name
☐ Inventor(s)/Applicant(s)
Assignee of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).
Filed under 37 CFR 1.34(a) Registration number if acting under 37 CFR 1.34(a)
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.
□ *Total offorms are submitted.